, /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from two studies of RADICAVA (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting. Findings from an ongoing real-world study utilizing information in the ALS/MND Natural History Study Consortium (Consortium) database of people living with ALS initiating treatment with RADICAVA suggest an additional survival benefit of 3.
2 months with RADICAVA ± riluzole compared to treatment with riluzole alone. Separately, positive results from Study MT-1186-A03 ( ), a Phase 3 study evaluating the long-term safety of RADICAVA ORS (edaravone), showed no new safety concerns and that RADICAVA ORS was well-tolerated during the 96-week study period. "Access to real-world data is critical for complex rare diseases like ALS, and we are proud to collaborate with the ALS/MND Consortium to bring important real-world insights to the clinical community," said , M.
D., Vice President of Medical Affairs at MTPA. "In addition, we are encouraged that our long-term Phase 3 safety extension study continues to demonstrate the safety and tolerability profile of RADICAVA.
" The ongoing real-world study evaluated treatment patterns, clinical outcomes, and survival of RADICAVA–treated people living with ALS from the ALS/MND NHC database. Individuals receiving RADICAVA ± riluzole (n=176) were matched to those receiving riluzole only (n=176) base.
